1. Home
  2. EXPD vs GMAB Comparison

EXPD vs GMAB Comparison

Compare EXPD & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expeditors International of Washington Inc.

EXPD

Expeditors International of Washington Inc.

N/A

Current Price

$188.96

Market Cap

24.2B

ML Signal

N/A

GMAB

Genmab A/S ADS

N/A

Current Price

$34.32

Market Cap

20.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EXPD
GMAB
Founded
1979
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2B
20.3B
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
EXPD
GMAB
Price
$188.96
$34.32
Analyst Decision
Hold
Strong Buy
Analyst Count
11
8
Target Price
$133.00
$39.56
AVG Volume (30 Days)
986.2K
2.8M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
1.03%
N/A
EPS Growth
4.02
N/A
EPS
3.74
N/A
Revenue
$6,920,948,000.00
N/A
Revenue This Year
$2.71
$17.85
Revenue Next Year
$3.74
$16.04
P/E Ratio
$50.55
$1.90
Revenue Growth
13.49
N/A
52 Week Low
$113.06
$23.62
52 Week High
$189.99
$35.43

Technical Indicators

Market Signals
Indicator
EXPD
GMAB
Relative Strength Index (RSI) 65.33 72.74
Support Level $157.54 $30.68
Resistance Level $188.86 $34.32
Average True Range (ATR) 3.47 0.69
MACD 0.23 0.17
Stochastic Oscillator 82.43 94.75

Price Performance

Historical Comparison
EXPD
GMAB

About EXPD Expeditors International of Washington Inc.

Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2025, Expeditors derived 36% of consolidated gross revenue from airfreight, 25% from ocean freight, and 39% from customs brokerage and other services.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: